Marburgvirus Infections R&D Pipeline Analysis Report, Q4 2020
Marburgvirus Infections Pipeline Overview
The Q4 Marburgvirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Marburgvirus Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Marburgvirus Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Marburgvirus Infections disease overview, Marburgvirus Infections types, Marburgvirus Infections symptoms, causes, and FDA/EMA approved treatment options.
Marburgvirus Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Marburgvirus Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Marburgvirus Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 19 companies. Business profiles and contact details of the companies actively perusing Marburgvirus Infections pipeline are assessed.
Marburgvirus Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Marburgvirus Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Marburgvirus Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Marburgvirus Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Marburgvirus Infections Pipeline Market News and Developments during 2020
The Marburgvirus Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Marburgvirus Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Marburgvirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Marburgvirus Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Marburgvirus Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Marburgvirus Infections disease overview, Marburgvirus Infections types, Marburgvirus Infections symptoms, causes, and FDA/EMA approved treatment options.
Marburgvirus Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Marburgvirus Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Marburgvirus Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 19 companies. Business profiles and contact details of the companies actively perusing Marburgvirus Infections pipeline are assessed.
Marburgvirus Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Marburgvirus Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Marburgvirus Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Marburgvirus Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Marburgvirus Infections Pipeline Market News and Developments during 2020
The Marburgvirus Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Marburgvirus Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Marburgvirus Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 19 companies are included including BioCryst Pharmaceuticals Inc, Collaborations Pharmaceuticals Inc, Eisai Co Ltd, Emergent BioSolutions Inc, Emergex Vaccines Ltd, Fab’entech SA, Flow Pharma Inc, Fox Chase Chemical Diversity Center Inc., GeoVax Labs Inc, Greffex Inc, IDBiologics Inc, Immunomodulation Inc, Integrated BioTherapeutics Inc, Intervir Therapeutics, Johnson & Johnson, Mapp Biopharmaceutical Inc, Phoenix Biotechnology Inc, Profectus BioSciences Inc, Rodos BioTarget GmbH,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Marburgvirus Infections pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. MARBURGVIRUS INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Marburgvirus Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Marburgvirus Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Marburgvirus Infections pipeline
2.5 Active Companies Developing Marburgvirus Infections pipeline
3. MARBURGVIRUS INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. MARBURGVIRUS INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 BioCryst Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Eisai Co Ltd
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Fab’entech SA
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc.
GeoVax Labs Inc
Greffex Inc
IDBiologics Inc
Immunomodulation Inc
Integrated BioTherapeutics Inc
Intervir Therapeutics
Johnson & Johnson
Mapp Biopharmaceutical Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
5. MARBURGVIRUS INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. MARBURGVIRUS INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. MARBURGVIRUS INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Marburgvirus Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Marburgvirus Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Marburgvirus Infections pipeline
2.5 Active Companies Developing Marburgvirus Infections pipeline
3. MARBURGVIRUS INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. MARBURGVIRUS INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 BioCryst Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Eisai Co Ltd
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Fab’entech SA
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc.
GeoVax Labs Inc
Greffex Inc
IDBiologics Inc
Immunomodulation Inc
Integrated BioTherapeutics Inc
Intervir Therapeutics
Johnson & Johnson
Mapp Biopharmaceutical Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
5. MARBURGVIRUS INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. MARBURGVIRUS INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
